Technology
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Published
2 years agoon
By
USA News Group Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Dec. 26, 2024 /CNW/ — USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system’s power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively targeting cancer cells while preserving healthy tissue. These innovations underscore the relentless pursuit of breakthroughs in oncology to enhance patient outcomes. Among the key players driving recent progress in the field are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Erasca, Inc. (NASDAQ: ERAS), Allogene Therapeutics, Inc. (NASDAQ: ALLO), Context Therapeutics Inc. (NASDAQ: CNTX), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).
The article continued: The oncology field continues to advance, with MarketsAndMarkets forecasting the Artificial Intelligence in Oncology Market to reach $11.52 billion by 2030, driven by a 29.4% CAGR. Similarly, Nova Advisor predicts the Personalized Cell Therapy Market will grow at a 23.53% CAGR, reaching $251.37 billion by 2034.
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, recently released a recap of major accomplishments from 2024 and a preview of anticipated milestones for the next 12 months. Following the promising BRACELET-1 readout, Oncolytics expects additional data readouts across its clinical development program in 2025, forming what it believes is a clear pathway to future commercialization opportunities.
“This past year produced highly encouraging clinical developments that we believe set the stage for significant progress, headlined by the robust efficacy results from the BRACELET-1 breast cancer study,” said Wayne Pisano, Interim CEO and Chair of Oncolytics Biotech’s Board of Directors. “In addition, our gastrointestinal cancer program continues to impress, resulting in meaningful collaborations with well-respected experts in the field. Key opinion leaders in both breast and GI cancers continue to be excited by pelareorep’s potential as we move into 2025. Based on these insights from leading oncologists, we believe pelareorep has the potential to become a transformational immunotherapy—and that pelareorep-based combination therapies could accelerate our path toward regulatory approval. We are very optimistic about our plans for the next year, and we look forward to showcasing our latest clinical progress early in the new year at the ASCO GI Symposium—an event that could provide key catalysts for our ongoing gastrointestinal cancer programs. Unlike many immunotherapies that struggle to convert ‘cold’ tumors to ‘hot,’ pelareorep’s unique mechanism of action following intravenous delivery has shown the potential to significantly boost patients’ immune responses—making previously unresponsive tumors more susceptible to treatment. I would like to say thank you to our shareholders, clinical collaborators, study sites and their staff, the patients who participate in our trials, and the employees of Oncolytics Biotech who have stepped up in a significant way in the temporary absence of our CEO, Matt Coffey.”
Oncolytics Biotech continues to advance pelareorep, its innovative immunotherapy for multiple cancer indications. Final efficacy results from the BRACELET-1 study in HR+/HER2- metastatic breast cancer demonstrated a median overall survival benefit exceeding one year and a two-year survival rate nearly double that of paclitaxel monotherapy. These findings, supported by earlier IND-213 data, further reinforce pelareorep’s transformative potential. With FDA alignment on a planned registration-enabling study, Oncolytics Biotech aims to offer improved treatment options for approximately 55,000 U.S. patients annually.
Significant progress has also been made in pancreatic cancer, with plans for a registration-enabling study supported by collaborations with the Global Coalition for Adaptive Research (GCAR) and Roche. This follows the GOBLET study’s outcomes, which more than doubled response rates in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. Additionally, the PanCAN-funded GOBLET cohort evaluating pelareorep plus mFOLFIRINOX, with or without atezolizumab, has completed safety run-in enrollment, receiving positive feedback from the Data Safety Monitoring Board. Key findings from this cohort, alongside progress in anal cancer, will be presented at the ASCO GI Symposium in January 2025.
Looking ahead, Oncolytics Biotech will present at the Biotech Showcase on January 13, 2025, and host investor meetings during the J.P. Morgan Healthcare Conference that same week. These events will provide a platform to highlight its clinical advancements and reinforce its commitment to addressing critical unmet needs in oncology.
CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/
In other recent industry developments and happenings in the market include:
Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company, recently provided updates on its R&D advancements targeting RAS/MAPK pathway-driven cancers. In October 2024, the company presented promising Phase 1b SEACRAFT-1 data for naporafenib plus trametinib (MEKINIST®), showing potential for an NRAS-mutated melanoma indication and supporting the ongoing Phase 3 SEACRAFT-2 trial. Erasca also announced progress on its pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 programs, confirming best-in-class potential and preparing for IND submissions in 2025. Key milestones include data from SEACRAFT-2 in 2025 and initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 in 2026.
“We made significant progress across our pipeline programs and are pleased with the pace of our execution,” said Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca. “Positive preliminary data from SEACRAFT-1, which we reported at the 36th EORTC-NCI-AACR (ENA) Symposium last month, has refined our clinical development focus of naporafenib plus trametinib on patients with NRAS-mutant (NRASm) melanoma, and importantly, heightens our conviction in the ongoing SEACRAFT-2 registrational trial targeting a similar patient population. SEACRAFT-2 has the potential for approval based on the high unmet need of these patients as well as the alignment with US and European regulators on the NRASm melanoma indication. We expect randomized dose optimization data from Stage 1 of this Phase 3 trial in 2025.”
Allogene Therapeutics, Inc. (NASDAQ: ALLO), a clinical-stage biotechnology company, recently announced new data from the Phase 1 TRAVERSE trial evaluating ALLO-316, its first AlloCAR T™ product candidate, for advanced or metastatic renal cell carcinoma (RCC). Presented at the 2024 IKCS and SITC Annual Meetings, the data demonstrated a 50% overall response rate (ORR) and a 33% confirmed response rate (CRR) in patients with CD70 Tumor Proportion Scores (TPS) ≥50%. ALLO-316 showed robust CAR T cell expansion, manageable safety, and durable tumor responses, supporting the FDA’s RMAT designation for advanced RCC. Additional data from the ongoing Phase 1b expansion cohort is expected in mid-2025.
“ALLO-316, the leading “off-the-shelf” CAR T product candidate currently in development for solid tumors, continues to show remarkable potency in the TRAVERSE trial,” said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer of Allogene. “Data from the Phase 1 study demonstrating significant anti-tumor activity in patients with metastatic disease resistant to multiple therapeutic classes, even with standard lymphodepletion, potentially marks a major advancement in the field. The unprecedented cell expansion and persistence driven by CD70 CAR-intrinsic Dagger® technology, along with strong evidence of tumor infiltration by CAR T cells, highlights the distinctive features of ALLO-316. We believe these findings from our Phase 1 trial lay the groundwork for a new generation of allogeneic cell therapies.”
Context Therapeutics Inc. (NASDAQ: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, recently announced advancements in its T cell-engaging bispecific antibody pipeline, including CT-202, a Nectin-4 x CD3 antibody licensed in September 2024, with an IND filing expected in mid-2026. Context also acquired CT-95, a Mesothelin x CD3 antibody, set to begin Phase 1 trials in Q1 2025. Additionally, Context will present data on its Claudin 6-targeting antibody CTIM-76 at the SITC Annual Meeting.
“Context executed on its strategy to build a pipeline of T cell engaging bispecific antibodies through its acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody,” said Martin Lehr, CEO of Context. “We continue to activate additional sites for our Phase 1 trial for CTIM-76, a Claudin 6 x CD3 bispecific antibody, and expect to dose our first patient by the end of this year. We also expect to advance CT-95 into the clinic soon and expect to enroll our first patient in our CT-95 Phase 1 study in the first quarter of 2025.”
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a clinical stage TechBio company, recently announced interim data from the Phase 1/2 ELUCIDATE trial of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The trial showed REC-617 was well-tolerated with no discontinuations due to adverse events, and one patient with platinum-resistant ovarian cancer achieved a confirmed partial response lasting over six months, while four others had stable disease for up to six months. With plans to continue dose escalation and initiate combination studies in early 2025, REC-617 demonstrates potential as a safe and effective therapy in heavily pre-treated cancer patients.
“Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive cancers,” said David Hallett, Ph.D., Chief Scientific Officer of Recursion. “By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level.”
CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.com/news-releases/oncology-in-focus-how-emerging-therapies-are-reshaping-cancer-treatment-302339333.html
SOURCE USA News Group
You may like
Technology
New GASA Research: 71% of Adults Surveyed Across 13 Asian Markets Encountered Scams, with Estimated Losses of US$136.5 Billion
Published
6 minutes agoon
October 22, 2026By
Research highlights a gap between confidence in recognizing scams and actual outcomes ahead of the Global Anti-Scam Summit Asia 2026
BANGKOK, Oct. 22, 2026 /PRNewswire/ — New research from the Global Anti-Scam Alliance (GASA), developed in collaboration with Gogolook, the developer of Whoscall, reveals the scale and impact of scams across Asia. Among adults surveyed in 13 Asian markets, 71% encountered a scam in the past year. The study estimates that consumers across those markets lost a combined US$136.5 billion to scams over the same period.
The State of Scams in Asia 2026 report, based on a survey of 17,460 adults, also identifies a gap between confidence and outcomes. While 66% of respondents said they were confident in their ability to recognize scams, 62% of those who encountered one interacted with it. Among respondents who interacted with a scam, 26% lost money.
The findings are being released ahead of the Global Anti-Scam Summit Asia 2026, taking place in Bangkok on 10–11 November. Following previous editions in Taiwan and Singapore, the summit will be held in Thailand for the first time, bringing together leaders from across sectors to strengthen the region’s response to evolving scams.
Phone calls and messages remain major points of exposure
Phone calls were the most common channel through which respondents encountered scams (56%), followed by text messages (50%) and instant messaging apps (40%). Shopping, investment and employment scams were the scam types respondents most commonly interacted with.
“Phone and text message scams remain a major challenge across Asia. In Thailand, Malaysia, Vietnam and Indonesia, more than six in ten respondents encountered scam calls. As scammers use AI-generated voices and increasingly convincing scripts, identifying suspicious numbers and warning users before they engage becomes even more important,” said Jeff Kuo, CEO of Gogolook. “Whoscall’s observations also suggest that scammers are adapting to tighter SIM registration and identity checks by using international and satellite numbers. That makes continued information sharing across markets essential.”
The harm extends beyond financial losses
The research estimates that consumers across the 13 markets lost US$136.5 billion to scams over the past 12 months. Among respondents who lost money, 51% said they had been scammed more than once.
The effects reached beyond the immediate financial loss. Among those who lost money, 72% reported an impact on their mental wellbeing, 77% experienced at least one emotional impact, and 58% experienced at least one financial impact affecting their everyday lives.
“One of the most striking findings is the gap between confidence and behavior. While 66% of respondents feel confident they can recognize scams, 62% of those who encountered one went on to interact with it. This shows why education is important but cannot be our only line of defense. We also need stronger safeguards that protect people throughout the scam journey.” said Brian D. Hanley, Director, Asia-Pacific Chapter, Global Anti-Scam Alliance (GASA).
Turning regional evidence into action
The findings will inform discussions at the Global Anti-Scam Summit Asia 2026, where representatives from government, law enforcement, financial services, technology, telecommunications, consumer protection and other sectors will explore ways to prevent and disrupt scams.
The research also points to public support for more proactive intervention. Across the markets surveyed, 71% supported allowing banks to block high-value transactions without a customer’s prior permission when they suspect a scam. Another 69% supported allowing telecom operators or messaging apps to block calls and messages they believe are malicious.
Reporting, however, does not always lead to recovery. While 85% of victims reported their scam experience, outcomes varied depending on where they reported it, and recovery and reimbursement remained limited.
Download the full State of Scams in Asia 2026 report here: https://gasa.org/knowledge-base/reports/state-of-scams-in-asia-2026
Registration for the Global Anti-Scam Summit Asia 2026 is open. For the programme and registration details, visit the summit website: https://gasa.org/global-anti-scam-summit-asia-2026
About the research
The State of Scams in Asia 2026 surveyed 17,460 adults across 13 Asian markets: China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam. Fieldwork was conducted between March 16 and April 13, 2026. The research was conducted by Opinium for the Global Anti-Scam Alliance and developed in collaboration with Gogolook, the developer of Whoscall.
About the Global Anti-Scam Alliance
The Global Anti-Scam Alliance (GASA) is a nonprofit organization bringing together policymakers, law enforcement, consumer authorities, NGOs, the financial sector, telecommunications operators, internet platforms, cybersecurity organizations and other stakeholders to share knowledge and develop solutions to protect consumers from scams.
GASA Website: https://gasa.org/
About Gogolook
Gogolook is a leading TrustTech company established in 2012. With “Build for Trust” as its core value, Gogolook has expanded its business from Asia to Europe and the Americas. As a foundation member of the Global Anti-Scam Alliance (GASA), Gogolook collaborates with law enforcement agencies and public-sector organizations, including the Taiwan National Police Agency, the Royal Thai Police, the Philippines Cybercrime Investigation and Coordinating Center, the Tokyo Metropolitan Police Department, and the Royal Malaysia Police. These partnerships support its commitment to building a scam-free environment.
Gogolook Website: https://www.gogolook.com/
About Whoscall
Whoscall, developed by Gogolook, is a caller ID and digital anti-scam app designed to protect users from scams across various channels, including phone calls, text messages, social media, and links. With over 100 million downloads globally, it features the most comprehensive database in East and Southeast Asia, covering more than 2.6 billion phone numbers.
Whoscall Website: https://web.whoscall.com/en
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/new-gasa-research-71-of-adults-surveyed-across-13-asian-markets-encountered-scams-with-estimated-losses-of-us136-5-billion-302914904.html
SOURCE Gogolook
Technology
Voqalize Says Voice Is Becoming the Default Way People Use Software
Published
6 minutes agoon
October 22, 2026By
Voqalize is infrastructure for making software conversational. Existing applications, websites and AI agents can add a voice interface that listens, sees context, responds and acts, without being rebuilt.
BENGALURU, India, Oct. 22, 2026 /PRNewswire/ — Voqalize today said it gives existing applications, websites and AI agents a voice interface that can listen, see context, respond and act, without rebuilding the application. The company says teams can have it running in about an hour, either through Plug & Play, where Voqalize manages the AI agent and the voice experience, or through a developer integration into their own backend.
Imagine telling a clothing app: “I’ve got an outdoor wedding in Napa on the 20th. I need something under two hundred that goes with the shoes I bought in the spring.” The app pulls those shoes from your order history and lays out six options beside them. “Not the floral. Show me the second one in the navy.” It swaps the color and puts the shoes next to it. Then it adds: “You sent back a medium from this brand last time, so I picked the large. It arrives on the 17th.” You look it over and tap buy. That is the shift Voqalize is building for: voice not as input, but as an interface to software.
Fast facts
Apple’s iOS 27, released in September, lets Siri read what’s on a user’s screen and take actions inside appsGoogle reports that roughly one in five Gemini Live conversations now add a camera or screen share, with voice used in 63% of interactions across Gemini’s 1 billion-plus monthly usersA Censuswide survey of 700 business leaders and consumers for Voices, published Jan. 28, 2026, found that 55% of consumers say voice is their primary AI interface, while only 29% of companies have deployed customer-facing voice AI
Dictation Proved People Will Talk to Their Software
Dictation and notetaking apps are among the fastest-growing categories in consumer AI. Wispr, valued at $2 billion, and Granola, valued at $1.5 billion, have both built large user bases on a simple premise: people would rather talk than type, once the transcription is good enough. Wispr says the habit sticks. After six months, its average user writes 72% of their characters by voice.
The category is already moving past that original pitch. Wispr raised its most recent round on a case for going “beyond dictation.” Granola is expanding from a meeting notetaker into what it describes as a context layer for company AI. Superhuman acquired the notetaker Fathom in September. Talking to software stopped being the hard part. What people do with that voice next, and how directly it’s built into the products they already use, is where the category is headed.
“The next billion people coming online won’t type their way onto the internet. They’ll talk their way on, in whatever mix of languages they speak at home.” Sripathi Krishnan, Co-founder, Voqalize
Voice Is Moving From Typing Substitute to Default Interface
Voqalize’s argument is that voice is moving from a typing substitute into the default way people use an app: a running conversation, not a single dictated sentence, where the app listens, responds and can act on what’s on screen, with the interruptions and mid-task changes of direction that come with a real conversation. That mirrors a broader shift already underway on the phone line, where most current “voice AI” is still built around short, scripted calls that book an appointment or qualify a lead and then hang up. Apple’s iOS 27 and Google’s Gemini Live both point at the same shift: voice agents that can see a screen and act on it rather than just transcribe speech.
How Do You Add a Voice Interface to an Existing App?
An existing application or device connects through Voqalize rather than being rebuilt inside a new platform: Voqalize supplies the two-way voice channel and the ability to read and act on whatever is on screen. Businesses choose how much to hand over. With Plug & Play, Voqalize manages the AI agent and the voice experience. With a developer integration, businesses add Voqalize’s voice capabilities to their own backend while keeping control of their AI agent and workflows.
In some deployments, that voice is paired with a face on screen as well, so the person on the other end has something to talk to, not just a voice in the room. Sripathi Krishnan, the company’s co-founder, has argued that the harder part of that conversation may not be how fluently the agent talks, but how well it listens and knows when to stay quiet. Voqalize also works across Indic languages, because conversations in India often move between languages mid-sentence. A majority of Indian internet users already engage with content in Indic languages. Voice also makes software accessible across languages and across literacy and input constraints.
Building Toward Plug-and-Play Voice, Across Apps and Devices
Today, adding Voqalize to a product means connecting an existing application or device through a single interface, without rebuilding it inside a new platform. Voqalize says its near-term work is on extending that same one-connection model further, so that adding two-way voice to a new app, or to a device beyond the phone and the browser, becomes a plug-and-play step rather than a custom integration. That direction follows a broader move already visible in the industry: voice infrastructure is consolidating around shared frameworks instead of one-off builds, and AI tools are increasingly connecting to each other through standard connectors rather than custom code written for each pairing. Voqalize says it intends to be the layer that makes that same simplicity available for voice specifically, across whatever app or device a company is already building for.
“Soon people will judge an app by how well it understands them, the way you judge a shop by whether the person behind the counter gets what you mean.” Samkeet Jain, Co-founder, Voqalize
Voqalize is available today for teams adding a two-way voice interface to an existing product or AI agent. Early deployments include in-app assistants for mortgage servicing workflows, legal clause review, and authenticated banking support. Voqalize was also named one of the 30 products in YourStory’s Vibecode30 2026, a showcase of emerging AI-native builders in India.
About Voqalize Voqalize is a voice AI platform that makes it easy for businesses to add two-way voice conversations to their applications and AI agents across 60+ Global and Indic languages. With Plug & Play, Voqalize manages the AI agent and voice experience for you. With our developer integration, businesses can add Voqalize’s voice capabilities to their own backend while keeping control of their AI agent and workflows. Go ahead and build your next voice-enabled applications with us on voqalize.com.
Media Contact: Samkeet Jain / +91 8147514179 / Samkeet@voqalize.com
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/voqalize-says-voice-is-becoming-the-default-way-people-use-software-302915851.html
Technology
Sungrow Advances Integrated C&I Microgrid Solution to Southeast Asia
Published
6 minutes agoon
October 22, 2026By
KUALA LUMPUR, Malaysia, Oct. 22, 2026 /PRNewswire/ — As Southeast Asia’s manufacturing sector expands, businesses face growing pressure from rising electricity costs, power supply disruptions and increasingly complex energy demands. Sungrow, a globally leading PV inverter and energy storage system provider, has launched the Integrated C&I Microgrid Solution for Southeast Asia, bringing together PV inverters, energy storage systems, EV chargers, microgrid controllers and cloud platforms. The solution helps businesses access more economical, reliable, and cleaner power.
End-to-End Cost Optimization, Improving Overall Benefits by 12%
For businesses seeking to reduce energy costs without compromising power reliability, system sizing and energy dispatch are critical. Sungrow’s Integrated C&I Microgrid Solution is engineered to make clean energy a more cost-competitive choice for businesses.
Optimized System Sizing: 8,760-hour simulations and intelligent algorithms evaluate tens of thousands of system configurations to optimize the capacity of PV, storage and diesel generation, helping avoid overinvestment and undersized systems.Intelligent Energy Dispatch: PV generation and load forecasts are updated every five minutes. Based on these forecasts and real-time electricity prices, AI dynamically optimizes the dispatch of multiple energy sources, including PV, energy storage and diesel generation, helping businesses meet their energy needs at a lower cost. This boosts overall economic benefits by 12% and shortens project payback periods by 1–2 years.Flexible Market Participation: Open interfaces and support for major electricity market protocols enable participation in diverse market mechanisms and unlock additional revenue streams.
Industry-First Five-Layer Protection for Reliable Power
For factories and commercial facilities, power outages can halt equipment, disrupt production and prolong recovery. Reliable power for critical loads is essential to keeping operations running.
Sungrow’s Integrated C&I Microgrid Solution features an industry-first five-layer protection framework, with tailored control strategies for different levels of grid disturbance. It can withstand three times overload for 10 seconds and severe voltage disturbances, helping protect critical loads from supply disruptions. With seamless grid-to-off-grid switching with no interruption to loads and whole-site black-start capability in just 3 minutes, the solution helps ensure a reliable power supply and rapid recovery during grid disruptions.
Support Throughout the Project Lifecycle
From system design and deployment to long-term operation, Sungrow simplifies the entire project lifecycle with full-stack in-house technologies and global service support.
Simplified Design and Deployment: One-stop system design, plug-and-play installation and one-click cloud connection streamline the journey from planning to commissioning.Smarter Operations: Coordinated PV, storage, EV charging, microgrid control and cloud management enable flexible energy dispatch, unified cloud-based management and automatic fault alerts.Global Service Support: With more than 520 service locations, 24/7 technical support and global spare parts centers, Sungrow helps keep projects running reliably over the long term.
Real-World Applications: Powering Energy Independence
“Sungrow’s Integrated C&I Microgrid Solution has been deployed across multiple locations in Southeast Asia, addressing diverse energy challenges for businesses,” said Huang Wanfeng, director of the Smart Energy Products Department at Sungrow.
In the Solomon Islands, the Solomon Resort Hotel Microgrid enables reliable off-grid hotel operations while helping reduce annual CO₂ emissions by around 1,000 tonnes and fuel costs by an estimated USD 600,000–700,000. Meanwhile, in Indonesia, Sungrow’s microgrid solution helps address power supply challenges in industrial parks, reducing reliance on diesel generation.
With proven experience across diverse applications, Sungrow is committed to helping businesses across Southeast Asia build more reliable, cost-efficient and resilient energy systems.
Contact:
Luly Wang
luly.wang@sungrow-hq.com
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/sungrow-advances-integrated-ci-microgrid-solution-to-southeast-asia-302916312.html
SOURCE Sungrow Power
New GASA Research: 71% of Adults Surveyed Across 13 Asian Markets Encountered Scams, with Estimated Losses of US$136.5 Billion
Voqalize Says Voice Is Becoming the Default Way People Use Software
Sungrow Advances Integrated C&I Microgrid Solution to Southeast Asia
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Near Videos5 days agoWhat if you could build a skyscraper with one prompt?
-
Technology5 days agoHighland and Bath Counties, Virginia Go Live on a Shared Caliber Hosted CAD Environment
-
Technology5 days agoJinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency
-
Technology4 days agoBioethanol from human hair – Indian start-up’s solution to rising prices of grains and sugar
-
Technology3 days agoGMIF2026: AI Inference Powers the “Token Factory” and Drives System-Level Rethinking of Memory & Storage
-
Technology4 days agoLinktel Technologies Highlights Breakthrough 1.6T LPO Performance & Strong Market Pull at OCP 2026
-
Coin Market3 days agoWorld Liberty’s USD1 stablecoin sheds $400M in market cap in two weeks
-
Technology3 days agoTruecaller announces preliminary numbers for the third quarter 2026
